论文部分内容阅读
目的:观察依达拉奉治疗急性脑出血的临床疗效。方法:将临床发病72 h内的脑出血患者随机分为治疗组和对照组,每组65例。治疗组在常规治疗的基础上给予依达拉奉30 mg加NaCl溶液100 ml静脉滴注,30 min内滴完,2次/d,14 d为1个疗程。结果:治疗组和对照组神经功能缺损评分治疗后明显下降。治疗组和对照组总有效率分别为89.23%和70.76%。两组总有效率比较差异有统计学意义(P<0.05)。两组均未发现明显不良反应。结论:依达拉奉治疗急性脑出血疗效显著、安全、有效,值得临床推广。
Objective: To observe the clinical efficacy of edaravone in the treatment of acute cerebral hemorrhage. Methods: The patients with intracerebral hemorrhage within 72 hours of clinical onset were randomly divided into treatment group and control group, with 65 cases in each group. The treatment group was given edaravone 30 mg plus NaCl solution 100 ml intravenously on the basis of routine treatment, drip finished 30 min, 2 times / d, 14 d for a course of treatment. Results: The neurological deficit scores of the treatment group and the control group decreased significantly after treatment. The total effective rate of the treatment group and the control group were 89.23% and 70.76% respectively. The total effective rate was significantly different between the two groups (P <0.05). No obvious adverse reactions were found in both groups. Conclusion: Edaravone treatment of acute cerebral hemorrhage significant effect, safe and effective, worthy of clinical promotion.